You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia
|
|---|---|
| Published in |
Molecular Psychiatry, May 2015
|
| DOI | 10.1038/mp.2015.11 |
| Pubmed ID | |
| Authors |
T W Weickert, D Weinberg, R Lenroot, S V Catts, R Wells, A Vercammen, M O'Donnell, C Galletly, D Liu, R Balzan, B Short, D Pellen, J Curtis, V J Carr, J Kulkarni, P R Schofield, C S Weickert |
| Abstract |
There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator, raloxifene, stimulates estrogen-like activity in brain and can improve cognition in older adults. The present study tested the extent to which adjunctive raloxifene treatment improved cognition and reduced symptoms in young to middle-age men and women with schizophrenia. Ninety-eight patients with a diagnosis of schizophrenia or schizoaffective disorder were recruited into a dual-site, thirteen-week, randomized, double-blind, placebo-controlled, crossover trial of adjunctive raloxifene treatment in addition to their usual antipsychotic medications. Symptom severity and cognition in the domains of working memory, attention/processing speed, language and verbal memory were assessed at baseline, 6 and 13 weeks. Analyses of the initial 6-week phase of the study using a parallel groups design (with 39 patients receiving placebo and 40 receiving raloxifene) revealed that participants receiving adjunctive raloxifene treatment showed significant improvement relative to placebo in memory and attention/processing speed. There was no reduction in symptom severity with treatment compared with placebo. There were significant carryover effects, suggesting some cognitive benefits are sustained even after raloxifene withdrawal. Analysis of the 13-week crossover data revealed significant improvement with raloxifene only in attention/processing speed. This is the first study to show that daily, oral adjunctive raloxifene treatment at 120 mg per day has beneficial effects on attention/processing speed and memory for both men and women with schizophrenia. Thus, raloxifene may be useful as an adjunctive treatment for cognitive deficits associated with schizophrenia.Molecular Psychiatry advance online publication, 18 May 2015; doi:10.1038/mp.2015.11. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 221 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 217 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 38 | 17% |
| Student > Ph. D. Student | 37 | 17% |
| Researcher | 23 | 10% |
| Student > Master | 20 | 9% |
| Student > Doctoral Student | 12 | 5% |
| Other | 50 | 23% |
| Unknown | 41 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 46 | 21% |
| Medicine and Dentistry | 42 | 19% |
| Neuroscience | 25 | 11% |
| Nursing and Health Professions | 13 | 6% |
| Agricultural and Biological Sciences | 10 | 5% |
| Other | 24 | 11% |
| Unknown | 61 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2020.
All research outputs
#980,880
of 22,805,349 outputs
Outputs from Molecular Psychiatry
#799
of 4,107 outputs
Outputs of similar age
#13,206
of 265,512 outputs
Outputs of similar age from Molecular Psychiatry
#15
of 51 outputs
Altmetric has tracked 22,805,349 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,107 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.3. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,512 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.